Related Experiment Video

Updated: Dec 17, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.8K

Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study

Andrea Marrari1,2, Alexia Bertuzzi1, Silvia Bozzarelli1

  • 1Medical Oncology and Hematology Unit.

Medicine
|June 27, 2020
PubMed
Abstract

Insights

Regorafenib demonstrated clinical activity in advanced soft tissue sarcomas (STS). This phase II trial showed a 61.9% progression-free survival at 8 weeks, indicating potential therapeutic benefit in pretreated patients.

Area of Science:

  • Oncology
  • Medical Oncology
  • Clinical Pharmacology

Background:

  • Regorafenib, a tyrosine kinase inhibitor, has shown activity in soft tissue sarcomas (STS).
  • Previous research suggests potential efficacy in this patient population.

Purpose of the Study:

  • To evaluate the clinical activity of regorafenib in advanced, pretreated soft tissue sarcoma (STS) patients.
  • To determine the progression-free survival (PFS) at 8 weeks as the primary endpoint.

Main Methods:

  • An open-label, non-randomized, single-center phase II study was conducted.
  • Patients received regorafenib 160 mg daily for 21 days of a 28-day cycle.
  • Progression-free survival (PFS) at 8 weeks and toxicity were assessed.

Main Results:

  • 61.9% of 21 evaluable patients were progression-free at 8 weeks.
  • Median PFS was 3.8 months; median overall survival was 14.8 months.
  • A 4.7% response rate and a 61.9% clinical benefit rate were observed; treatment was well tolerated.

Conclusions:

  • Regorafenib exhibits clinical activity in patients with advanced soft tissue sarcomas (STS).
  • The drug is a potential treatment option for pretreated STS patients.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.4K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K